Hydrocortison Panpharma (Hydrocortisone Hydrogen Succinate)

Hydrocortison Panpharma is indicated for several acute medical situations where swift glucocorticoid effect is needed.

• Replacement therapy in adrenal insufficiency (e.g., Addison’s disease or secondary adrenal failure).
• Management of acute adrenal crisis or shock.
• Treatment of severe systemic inflammatory or allergic reactions, such as anaphylaxis.
• Adjunctive therapy in severe asthma exacerbations or other life‑threatening inflammatory conditions.
• Supportive care in septic shock when cortisol response is inadequate.

• Hydrocortison Panpharma delivers hydrocortisone hydrogen succinate, which is rapidly converted to active hydrocortisone after intravenous infusion. The active molecule binds intracellular glucocorticoid receptors, translocates to the nucleus, and modulates gene transcription. This results in decreased synthesis of pro‑inflammatory cytokines, inhibition of phospholipase A2, and suppression of leukocyte migration, collectively reducing inflammation and dampening immune activation. It also stabilizes lysosomal membranes and reduces capillary permeability.

Adverse reactions to Hydrocortison Panpharma can vary from mild and transient to rare but serious events.

Common

• Transient hyperglycemia or elevated blood glucose.
• Mild electrolyte disturbances such as sodium retention or potassium loss.
• Headache, dizziness, or flushing.
• Local irritation at the infusion site.
• Nausea or vomiting.
• Insomnia or mood changes.
• Mild muscle weakness.

Serious

• Severe infection or sepsis due to immunosuppression.
• Acute adrenal crisis on abrupt discontinuation.
• Allergic reactions including rash, urticaria, or anaphylaxis.
• Psychiatric disturbances such as psychosis or severe mood swings.
• Osteonecrosis of the femoral head (rare).

When prescribing Hydrocortison Panpharma, clinicians should evaluate several safety considerations to minimize risk.

• Assess for active infections; glucocorticoids can worsen bacterial, viral, or fungal diseases.
• Monitor blood glucose and electrolytes, especially in diabetic or renal‑impaired patients.
• Use the lowest effective dose and limit duration to reduce adrenal suppression.
• Evaluate for a history of peptic ulcer disease or gastrointestinal bleeding.
• Consider pregnancy and lactation status; safety data are limited.
• Review concomitant medications that may increase bleeding risk or affect cortisol metabolism.
• Adjust dosage in patients with hepatic impairment, as metabolism may be altered.

Hydrocortison Panpharma may interact with other agents that influence cortisol metabolism or immune function.

Avoid

• Strong CYP3A4 inducers such as rifampin, phenytoin, or carbamazepine, which can reduce glucocorticoid levels.
• Live vaccines, because immunosuppression may diminish vaccine efficacy and increase infection risk.

Use with caution

• Anticoagulants (e.g., warfarin) due to potential enhancement of anticoagulant effect.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) because of additive risk of gastrointestinal ulceration.
• Diuretics that may exacerbate electrolyte imbalances.
• Antidiabetic agents, as glucocorticoids can raise blood glucose requiring dose adjustment.